Expression of SART3 tumor-rejection antigen in gastric cancers

Fumihiko Niiya, Shinya Nishizaka, Kazuko Matsunaga, Kikuo Koufuji, Masaki Mori, Hitoshi Katai, Hideaki Yamana, Kyogo Itoh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalJapanese Journal of Cancer Research
Volume91
Issue number3
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Neoplasm Antigens
Stomach Neoplasms
Histocompatibility Antigens
HLA Antigens
Cytotoxic T-Lymphocytes
Immunotherapy
Peptides
Antigens
Blood Cells
Stomach
Cell Line
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Niiya, F., Nishizaka, S., Matsunaga, K., Koufuji, K., Mori, M., Katai, H., ... Itoh, K. (2000). Expression of SART3 tumor-rejection antigen in gastric cancers. Japanese Journal of Cancer Research, 91(3), 337-342. https://doi.org/10.1111/j.1349-7006.2000.tb00950.x

Expression of SART3 tumor-rejection antigen in gastric cancers. / Niiya, Fumihiko; Nishizaka, Shinya; Matsunaga, Kazuko; Koufuji, Kikuo; Mori, Masaki; Katai, Hitoshi; Yamana, Hideaki; Itoh, Kyogo.

In: Japanese Journal of Cancer Research, Vol. 91, No. 3, 01.01.2000, p. 337-342.

Research output: Contribution to journalArticle

Niiya, F, Nishizaka, S, Matsunaga, K, Koufuji, K, Mori, M, Katai, H, Yamana, H & Itoh, K 2000, 'Expression of SART3 tumor-rejection antigen in gastric cancers', Japanese Journal of Cancer Research, vol. 91, no. 3, pp. 337-342. https://doi.org/10.1111/j.1349-7006.2000.tb00950.x
Niiya, Fumihiko ; Nishizaka, Shinya ; Matsunaga, Kazuko ; Koufuji, Kikuo ; Mori, Masaki ; Katai, Hitoshi ; Yamana, Hideaki ; Itoh, Kyogo. / Expression of SART3 tumor-rejection antigen in gastric cancers. In: Japanese Journal of Cancer Research. 2000 ; Vol. 91, No. 3. pp. 337-342.
@article{1ee334a4bf604f8eb2b788fae07d3fb3,
title = "Expression of SART3 tumor-rejection antigen in gastric cancers",
abstract = "We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90{\%}) gastric cancer cell lines, 35 of 52 (67.3{\%}) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.",
author = "Fumihiko Niiya and Shinya Nishizaka and Kazuko Matsunaga and Kikuo Koufuji and Masaki Mori and Hitoshi Katai and Hideaki Yamana and Kyogo Itoh",
year = "2000",
month = "1",
day = "1",
doi = "10.1111/j.1349-7006.2000.tb00950.x",
language = "English",
volume = "91",
pages = "337--342",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Expression of SART3 tumor-rejection antigen in gastric cancers

AU - Niiya, Fumihiko

AU - Nishizaka, Shinya

AU - Matsunaga, Kazuko

AU - Koufuji, Kikuo

AU - Mori, Masaki

AU - Katai, Hitoshi

AU - Yamana, Hideaki

AU - Itoh, Kyogo

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

AB - We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0034074197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034074197&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2000.tb00950.x

DO - 10.1111/j.1349-7006.2000.tb00950.x

M3 - Article

C2 - 10760694

AN - SCOPUS:0034074197

VL - 91

SP - 337

EP - 342

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 3

ER -